Organization
Department of Hepatobiliary and Pancreatic Surgery, Tianjin First Central Hospital，Nankai University, Tianjin, China
1 abstract
Abstract
Regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma efficacy and safety of patients: A real-world study.Org: Department of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin, China, Department of Hepatobiliary and Pancreatic Surgery, Tianjin First Central Hospital，Nankai University, Tianjin, China, Nankai University, Tianjin, China, Tianjin medical University, Tianjin, China,